Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia.
[1][2] The most common side effects include allergic reactions.
[1] Pegzilarginase was approved for medical use in the European Union in December 2023.
[1][2] In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia.
[1] Pegzilarginase was approved for medical use in the European Union in December 2023.